Altimmune, Inc.

Altimmune, Inc. is an active clinical-stage biotechnology company headquartered in Gaithersburg, Maryland specializing primarily in innovative peptide-based therapeutics targeting metabolic disorders such as obesity and liver disease including NASH/MASH. Their pipeline also includes immunotherapies against chronic viral infections like hepatitis B virus, cancer-targeting conjugated immunostimulants, intranasal vaccines against influenza (NasoVAX), plus government-backed anthrax vaccine candidates. Publicly traded under ticker symbol "ALT" on Nasdaq since before their recent inclusion into the Nasdaq Biotechnology Index reflects their growing prominence within biotech investing circles. Founded circa 1997 with plans for workforce expansion aligned with advancing multiple promising drug candidates through various stages of clinical development.